Raloxifene | compare suppliers & send inquiries for free
Looking for Raloxifene 84449-90-1?
- API | Excipient name:
- Raloxifene
- Synonyms:
- Keoxifene, LY 139481, RAL, Raloxifene, Raloxifeno, Raloxifenum, Raloxifene hydrochloride
- Cas Number:
- 84449-90-1
- DrugBank number:
- DB00481
- Unique Ingredient Identifier:
- YX9162EO3I
About Raloxifene
What makes Raloxifene unique? Raloxifene is a second generation selective estrogen receptor modulator (SERM) that mediates anti-estrogenic effects on breast and uterine tissues, and estrogenic effects on bone, lipid metabolism, and blood coagulation Exhibiting tissue-specific effects distinct from estradiol, raloxifene is the first of the benzothiophene group of antiestrogens to be labelled a SERM. Available in many countries worldwide, raloxifene was initially approved by the FDA in December, 1997 under the market name Evista® for the management and prevention of osteoporosis in postmenopausal women and reduction in risk for invasive breast cancer in postmenopausal women with osteoporosis or those who are at high risk for invasive breast cancer. However, it has a negligible effect on altering the development and progression of breast cancer itself. The most common causes of osteoporosis include postmenopausal deficiency of estrogen and age-related deterioration in bone homeostasis.
Due to the risk of bone fractures that may lead to morbidities and reduced quality of life, the management of osteoporosis in postmenopausal women with the use of therapeutic agents in addition to concurrent therapies is critical. Due to the decline in estrogen levels in postmenopausal osteoporosis, hormone replacement therapy (HRT), such as estradiol, has been used to ameliorate the condition. However, due to the off-target actions by HRT, newer non-hormonal agents such as raloxifene and tamoxifen have been developed to reduce adverse events through selective pharmacological actions on tissue-specific therapeutic targets. The main effects of raloxifene are to preserve the bone mineral density and decrease the risk of breast cancer in postmenopausal women. Compared to estrogen and tamoxifen, raloxifene was not associated with an increased risk of uterine cancer and it does not cause endometrial proliferation.
You can ask the supplier about all relevant certificates for the product such as CoA, Safety Data Sheet and DMF.
Raloxifene manufacturers | traders | suppliers
We have 17 companies offering Raloxifene from 4 different countries.
Get in contact with the supplier of your choice:
- Aurobindo from India
- Hetero Drugs from India
- omicron pharma from India
- Aarti Drugs from India
- Erregierre from Italy
- Apotex Pharmachem from India
- Cadila Pharma from India
- Dr. Reddy's from India
- Olon from Italy
- Teva from Israel
- Torrent Pharma from India
- Glochem from India
- Cambrex from Italy
- Cipla from India
- Hanmi Fine Chemical from South Korea
- Raks Pharma from India
- Sai-Tech Pharmaceuticals Pvt. Ltd. from India
Let the supplier know whether you are looking for a product with a specific monograph such as EP (Ph. Eur.), USP, JP, BP or another quality. Or, whether you are looking for hydrochloride (HCl), anhydricum, base, micronisatum or a specific purity.
You can use the filters to find high-quality suppliers. For example, you can select GMP, FDA or ISO certified suppliers. Visit our FAQ page or use the chat box in the corner to get more information about Pharmaoffer.